第15届世界肺癌大会非小细胞肺癌放疗研究进展

Advances in treatment of radiation of non-small-cell lung cancer in the 15th World Conference on Lung Cancer

第15届世界肺癌大会（WCLC）共收到约210篇放疗相关研究的摘要。内容涉及早期非小细胞肺癌（NSCLC）应用体部立体定向放疗（SBRT）的疗效和安全性、评价手段和剂量分割探讨；局部晚期NSCLC同步放化疗中高剂量与标准放疗剂量、不同化疗方案以及是否联合西妥昔单抗的对照研究；经全切的ⅢA～N2期NSCLC患者术后采用三维适行放疗（3D-CRT）的临床意义；NSCLC多发脑转移行全脑放疗（WBRT）同步联合酪氨酸激酶抑制剂（TKI）的疗效和安全性以及表皮生长因子受体（EGFR）突变状态对疗效的影响。另外关于放疗的防护、毒性、疗效、预后及生活质量评估也多有报告。

The 15th World Conference on Lung Cancer （WCLC） received about 210 abstracts on radiotherapy. These abstracts covered many realms, including the efficacy, safety, evaluation methods and dose fractionation study of stereotactic body radiotherapy （SBRT） on early stage non-small-cell lung cancer （NSCLC）; control studies of high and standard radiation dose, different chemotherapy regimens and whether combined cetuximab in concurrent radiochemotherapy on locally advanced NSCLC clinical significance of postoperative 3D-conformal radiotherapy （3D-CRT） for patients with pⅢA-N2 NSCLC after complete resection; the efficacy and safety of TKIs in combination with whole brain radiation therapy （WBRT） in NSCLC patients with multiple brain metastases, as well as the influence of EGFR mutation status on the curative effect. Besides, there are many reports about radiotherapy protection, toxicity, efficacy, prognosis and life quality assessment.